Truist analyst Richard Newitter lowered the firm’s price target on Edwards Lifesciences (EW) to $89 from $92 and keeps a Hold rating on the shares. The company’s Q4 revenue beat was driven by continued double-digit TAVR momentum and upside but with limited flowthru to EPS, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $87 from $90 at Baird
- Edwards Lifesciences: Capitalizing on TAVR Tailwinds, New Structural Heart Catalysts, and Attractive Valuation Upside
- Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating
- Buy Rating on Edwards Lifesciences Driven by Strong Core TAVR Momentum, Conservative 2026 Guidance, and Attractive Risk‑Reward Profile
- Edwards Lifesciences price target lowered to $95 from $108 at Goldman Sachs